Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford Department of Pharmacology has been judged best in the world for the second year in a row in the QS World Rankings, published today.

Pharmacology is one of eight subject areas at Oxford that top the World Rankings for 2020 - in increase from the five top place rankings in 2019. The University of Oxford secured the highest number of top place subject rankings for a UK institution for the second year running.

Jack Moran, QS Spokesperson, said: “It is a testament to the University of Oxford’s enduring quality that it has not just kept pace with the rate of improvement enjoyed by highly-ambitious, well-funded peers abroad – but has actually managed to continue raising the bar in many areas. A deeper delve into our dataset highlights the outstanding regard in which Oxford’s graduates are held, and the extraordinary impact of the academic inquiry taking place among the spires.”

Each of the subject rankings is compiled using four sources. The first two of these are QS’s global surveys of academics and employers (83,000 academics and 42,000 employers), which are used to assess institutions’ international reputation in each subject. The second two indicators assess research impact, based on research citations per paper and h-index in the relevant subject. These are sourced from Elsevier’s Scopus database, the world’s most comprehensive research citations database. 

Similar stories

Anthony group research offers new treatment hope for ALS patients

New research, led by the Anthony Group in Pharmacology and funded by GeNeuro, suggests a pathway to a new precision medicine approach for patients with amyotrophic lateral sclerosis (ALS). The groundbreaking findings were presented at the 35th International Symposium on ALS/MND, which took place in Montreal, Canada, from 6-8 December 2024.